myTomorrows, an Amsterdam-based health technology company, has secured a $29 million investment from a US-based healthcare-focused investment firm, Avego, to connect patients with pre-approval treatments.
The company aims to address a significant gap in healthcare, with the company citing that more than 300 million patients worldwide live with conditions for which no approved treatments currently exist, despite over 10,000 therapies being developed or reviewed globally. myTomorrows’ platform enables physicians and patients to identify opportunities for clinical trials and expanded access programs (EAPs), helping bridge this divide.
Funding to Drive AI Innovation and Global Reach
According to the announcement, the new capital will support the development of the firm’s AI-driven infrastructure, which connects patients, physicians, trial sites, and BioPharma partners. The platform is designed to streamline access, improve real-world data capabilities, and shorten clinical development timelines.
CEO Michel van Harten described the investment as a “pivotal step” in expanding equitable access to emerging therapies, highlighting Avego’s life sciences expertise as a key asset for future growth. Avego Managing Partner James Flexner said the firm believes myTomorrows “is uniquely positioned to remove barriers for patients and providers” while supporting BioPharma companies.
myTomorrows describes its long-term goal as building the default global gateway for pre-approval therapies—an infrastructure that supports AI-enabled insights, adaptive regulatory pathways and patient empowerment. With the new funding, the company intends to expand its role within healthcare systems worldwide and ensure that emerging therapies can reach patients “exactly when it matters.”
